Pliant Therapeutics Inc (PLRX)

$1.29 -0.04 (-3.01%)
Market Cap 79.87M
Revenue (ttm) 0.00
Net Income (ttm) -149.34M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 443,300
Avg Vol 789,332
Day's Range N/A - N/A
Shares Out 61.92M
Stochastic %K 12%
Beta 1.32
Analysts Hold
Price Target $2.67

Company Profile

Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonal...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 481 6770
Address:
331 Oyster Point Boulevard, South San Francisco, United States
THSSKS
THSSKS Mar. 20 at 6:04 AM
$PLRX amazing this went down/flat after being selected for AACR. Only a fraction of applicants are selected to be in. Hedgies might be accumulating to run it up next month after the meeting, usually only “best in class” make it which is why I’m surprised it went down after the news. Big investors will be watching April 18th. I’d like to see a big player like $MRK opt in here and give milestone payments. This could easily run 500% + if so. I bought back my position after that tiny sell off. Still close to $200M here with an $82MM mkt cap and a good portion of the float locked up. Downside limited because of cash, I’d think if pln-101095 failed, they’d at least remove the poison pill and let Tang buy the company for the cash or reverse merger..
1 · Reply
THSSKS
THSSKS Mar. 16 at 6:00 PM
$PLRX I can’t see the reports from Piper and Cannacord, but analysts must think the pipeline is worth absolute dog shit if they’re giving this a $3 pt which is near liquidation prices. Someone is relentlessly selling blocks the last couple of days too, definitely a fund that wants out. I was in this for a buyout which isn’t happening now, so good luck to everyone. I’m not letting this turn into another KZR who is still doing nothing after 2 years of poison pills to stop Tang, they had way more cash to market cap than plrx too 2 years ago. Management is screwing shareholders here pursuing new pipeline instead of finding alternatives. ✌️
2 · Reply
Stockboi_
Stockboi_ Mar. 13 at 5:47 PM
$PLRX need to hold support and we see higher. Strong daily chart
0 · Reply
NorthStarStats
NorthStarStats Mar. 13 at 11:57 AM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $APD Score: 100, $MOS Score: 95, $PLRX Score 71, $SBUX Score 70, $AWK Score 70
0 · Reply
anachartanalyst
anachartanalyst Mar. 12 at 5:02 PM
$PLRX https://anachart.com/wp-content/uploads/ana_temp/1773334907_soc-img.jpg
0 · Reply
sandman7473
sandman7473 Mar. 12 at 2:13 PM
$PLRX inverse head and shoulders setting up.
0 · Reply
THSSKS
THSSKS Mar. 12 at 3:45 AM
$PLRX overall data is encouraging but only 10 patients. This might need bigger phase 2 data to pop, hopefully I’m wrong but I don’t think so. roughly 2m patients worldwide receive checkpoint inhibitors. ~$100,000 per person implies a multi billion TAM. Board needs to buy stock
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 12 at 1:00 AM
$PLRX Q4 '25 Earnings Results & Recap Pliant Therapeutics expects research and development expenses and general and administrative expenses to decrease in 2026 due to reprioritization and restructuring, with existing capital sufficient for the next 12 months and beyond.
0 · Reply
focafoca99
focafoca99 Mar. 11 at 10:33 PM
$PLRX said Phase 1 data showed deep and durable responses in checkpoint-inhibitor-refractory solid tumors
0 · Reply
sandman7473
sandman7473 Mar. 11 at 8:30 PM
$PLRX positive data.
0 · Reply
Latest News on PLRX
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

Mar 18, 2026, 9:00 AM EDT - 3 days ago

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

Mar 11, 2026, 4:05 PM EDT - 10 days ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

Stock Picks From Seeking Alpha's February 2026 New Analysts

Mar 6, 2026, 8:00 AM EST - 15 days ago

Stock Picks From Seeking Alpha's February 2026 New Analysts

BMBL COST EZPW LULU NU PGY SFL

Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration

Feb 24, 2026, 1:28 AM EST - 26 days ago

Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration

Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference

Feb 23, 2026, 8:00 AM EST - 26 days ago

Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference

Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

Dec 4, 2025, 1:53 PM EST - 3 months ago

Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

MRK

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Dec 4, 2025, 7:30 AM EST - 3 months ago

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

Dec 1, 2025, 8:30 AM EST - 3 months ago

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 4 months ago

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 8 months ago

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Pliant Therapeutics Provides Update on BEACON-IPF

Jun 27, 2025, 4:05 PM EDT - 9 months ago

Pliant Therapeutics Provides Update on BEACON-IPF

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

May 21, 2025, 4:03 PM EDT - 10 months ago

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 11 months ago

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

May 1, 2025, 4:05 PM EDT - 11 months ago

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

Apr 7, 2025, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

Pliant Therapeutics: An Activist On Deck

Apr 3, 2025, 12:22 PM EDT - 1 year ago

Pliant Therapeutics: An Activist On Deck

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

Mar 13, 2025, 11:04 AM EDT - 1 year ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

Mar 13, 2025, 7:20 AM EDT - 1 year ago

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Mar 3, 2025, 4:05 PM EST - 1 year ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder

Mar 3, 2025, 1:32 PM EST - 1 year ago

Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Mar 3, 2025, 9:27 AM EST - 1 year ago

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

The Schall Law Firm Invites Shareholders With Losses In Pliant Therapeutics, Inc. To Join A Securities Fraud Investigation

Mar 2, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Shareholders With Losses In Pliant Therapeutics, Inc. To Join A Securities Fraud Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Shareholders to Inquire about Securities Investigation

Feb 27, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Connect

Feb 26, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Reach Out

Feb 25, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Shareholders to Learn More About the Investigation

Feb 24, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Shareholders to Learn More About the Investigation

Pliant Therapeutics, Inc. (PLRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 23, 2025, 10:00 AM EST - 1 year ago

Pliant Therapeutics, Inc. (PLRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Connect

Feb 21, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Connect

PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Feb 20, 2025, 3:39 PM EST - 1 year ago

PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Stockholders to Inquire about Securities Investigation

Feb 20, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Stockholders to Inquire about Securities Investigation

THSSKS
THSSKS Mar. 20 at 6:04 AM
$PLRX amazing this went down/flat after being selected for AACR. Only a fraction of applicants are selected to be in. Hedgies might be accumulating to run it up next month after the meeting, usually only “best in class” make it which is why I’m surprised it went down after the news. Big investors will be watching April 18th. I’d like to see a big player like $MRK opt in here and give milestone payments. This could easily run 500% + if so. I bought back my position after that tiny sell off. Still close to $200M here with an $82MM mkt cap and a good portion of the float locked up. Downside limited because of cash, I’d think if pln-101095 failed, they’d at least remove the poison pill and let Tang buy the company for the cash or reverse merger..
1 · Reply
THSSKS
THSSKS Mar. 16 at 6:00 PM
$PLRX I can’t see the reports from Piper and Cannacord, but analysts must think the pipeline is worth absolute dog shit if they’re giving this a $3 pt which is near liquidation prices. Someone is relentlessly selling blocks the last couple of days too, definitely a fund that wants out. I was in this for a buyout which isn’t happening now, so good luck to everyone. I’m not letting this turn into another KZR who is still doing nothing after 2 years of poison pills to stop Tang, they had way more cash to market cap than plrx too 2 years ago. Management is screwing shareholders here pursuing new pipeline instead of finding alternatives. ✌️
2 · Reply
Stockboi_
Stockboi_ Mar. 13 at 5:47 PM
$PLRX need to hold support and we see higher. Strong daily chart
0 · Reply
NorthStarStats
NorthStarStats Mar. 13 at 11:57 AM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $APD Score: 100, $MOS Score: 95, $PLRX Score 71, $SBUX Score 70, $AWK Score 70
0 · Reply
anachartanalyst
anachartanalyst Mar. 12 at 5:02 PM
$PLRX https://anachart.com/wp-content/uploads/ana_temp/1773334907_soc-img.jpg
0 · Reply
sandman7473
sandman7473 Mar. 12 at 2:13 PM
$PLRX inverse head and shoulders setting up.
0 · Reply
THSSKS
THSSKS Mar. 12 at 3:45 AM
$PLRX overall data is encouraging but only 10 patients. This might need bigger phase 2 data to pop, hopefully I’m wrong but I don’t think so. roughly 2m patients worldwide receive checkpoint inhibitors. ~$100,000 per person implies a multi billion TAM. Board needs to buy stock
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 12 at 1:00 AM
$PLRX Q4 '25 Earnings Results & Recap Pliant Therapeutics expects research and development expenses and general and administrative expenses to decrease in 2026 due to reprioritization and restructuring, with existing capital sufficient for the next 12 months and beyond.
0 · Reply
focafoca99
focafoca99 Mar. 11 at 10:33 PM
$PLRX said Phase 1 data showed deep and durable responses in checkpoint-inhibitor-refractory solid tumors
0 · Reply
sandman7473
sandman7473 Mar. 11 at 8:30 PM
$PLRX positive data.
0 · Reply
islandpunk
islandpunk Mar. 11 at 8:07 PM
$PLRX https://www.stocktitan.net/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-fourth-9po7v43kkgxz.html
0 · Reply
Lyn30
Lyn30 Mar. 11 at 12:38 PM
$PLRX Nice
0 · Reply
SurdifiedStocks
SurdifiedStocks Mar. 10 at 6:22 PM
$PLRX That was likely the top folks.
0 · Reply
JacobJones1
JacobJones1 Mar. 10 at 5:31 PM
$PLRX gonna keep climbing. Just getting started.
0 · Reply
Creyedr
Creyedr Mar. 10 at 2:31 PM
$PLRX let's go
0 · Reply
sandman7473
sandman7473 Mar. 10 at 1:55 PM
$PLRX 👀
1 · Reply
sandman7473
sandman7473 Mar. 9 at 2:10 PM
$PLRX reports today after hours I believe.
1 · Reply
Lyn30
Lyn30 Mar. 7 at 10:39 PM
$PLRX Hope it’s finally started , many back and forth
0 · Reply
dtankersley
dtankersley Mar. 6 at 7:52 PM
$PLRX LFG!
0 · Reply
THSSKS
THSSKS Mar. 5 at 9:41 AM
$PLRX these loser insiders are desperately trying to stop a sale of the company yet they never buy any shares either. If they believe in the pipeline so much, they should be buying shares at all time lows or just liquidating the company for a few dollars per share. They better start pumping this up and getting me to at least 400% profits somehow
1 · Reply
sandman7473
sandman7473 Mar. 4 at 2:21 PM
$PLRX https://www.tipranks.com/news/company-announcements/pliant-therapeutics-extends-stockholder-rights-agreement-expiration They extended the “poison pill” for another year. Interesting? 🧐
2 · Reply
bxlams
bxlams Mar. 3 at 11:31 PM
$PLRX asking for the stock to move isn't asking for the stock to dump btw
0 · Reply